IMDC risk → first-line regimen choice (RCC)
A simple clinical score decides between two immunotherapies together or one immunotherapy with a targeted pill.
Intermediate/poor risk: nivolumab-ipilimumab (durable remissions, treatment-free survival) or an IO-TKI doublet (higher response rate, less primary progression). Favourable risk: IO-TKI doublet or TKI alone, since IO-IO shows no OS gain there. Sarcomatoid features favour IO-based therapy regardless of risk.
Pages like this
not linked directly; found by shared links- TrialCheckMate 214
Shares IMDC risk groups (favourable / intermediate / poor), Sarcomatoid differentiation (RCC), Ipilimumab, Nivolumab.
- TrialKEYNOTE-426
Shares IMDC risk groups (favourable / intermediate / poor), Axitinib, Renal cell carcinoma, Pembrolizumab.
- TrialCLEAR (KEYNOTE-581)
Shares IMDC risk groups (favourable / intermediate / poor), Lenvatinib, Renal cell carcinoma, Pembrolizumab.
- TrialCOSMIC-313
Shares Cabozantinib, Ipilimumab, Nivolumab, Renal cell carcinoma.
- TrialLITESPARK-012
Shares Lenvatinib, Renal cell carcinoma, Pembrolizumab.
- IdeaPublicly funded dose-reduction trials of expensive approved drugs
Shares Nivolumab, Pembrolizumab, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
- TermImmune-related endocrinopathies (thyroiditis, hypophysitis)
Shares Ipilimumab, Nivolumab, Pembrolizumab, Immune checkpoint inhibitors.
- PairingCaution: PD-1 rechallenge after progression on immunotherapy (RCC)
Shares Cabozantinib, Nivolumab, Renal cell carcinoma, Immune checkpoint inhibitors.